Meduloc LLC receives US patent issuance

October 2020

Meduloc LLC today announced it has received US patent issuance for its novel intramedullary fixation device.  Meduloc’s intermedullary fixation system is designed to treat small, long-bone fractures (fingers, feet, clavicle, radius and ulna).  It provides the surgeon superior fracture reduction, fixation and rotational stability and utilizes a minimally invasive, soft tissue sparing surgical approach. 


Meduloc LLC is one of Cor Medical Ventures’ portfolio companies which is currently raising a $1M seed round of funding to complete the required testing and regulatory approvals needed to bring this technology to the market.


Smith+Nephew expands in higher-growth extremities segment through planned acquisition of Integra LifeSciences' Extremity Orthopaedics business

September 2020


Cor Medical Ventures congratulates Integra and S&N for this mutually beneficial transaction. The team at Cor have been instrumental in the development of several of Integra’s extremity technologies which increased the value of this transaction. Cor is proud to partner with companies like Integra and Smith+Nephew as they advance the care of patients around the world.


Cor Medical Ventures headquarters move to Del Mar, California

August 2020

In order to support our continued growth, Cor Medical Ventures has moved our offices one exit south to:

2010 Jimmy Durante Blvd. Suite 200 Del Mar, CA  


Our new location will feature an expanded prototype machine shop and additive manufacturing lab, along with flexible, open-plan office space.


We are grateful for the opportunity to work with so many great companies, surgeons, and inventors. Despite the challenges and difficulties the medical device industry has faced in 2020, we continue to accelerate product development, clinical studies, and regulatory approvals for our clients.

During this challenging time, Cor Medical Ventures’ focus is on supporting our customers, clients, employees, and the communities in which we work. We have successfully worked to avoid disruptions caused by COVID-19 coronavirus, while at the same time acting responsibly to do what we can to prevent further spread of the virus. We will continue to closely monitor and assess the evolving situation and will be diligent about communicating on important issues. As a result, we have suspended all non-essential travel at this time. We will continue to attend and support virtual meetings in the meantime. We look forward to seeing you all in the coming months once it is safe for all of us to attend.